Prostate cancer and the androgen receptor gene

Clinical and Translational Oncology

Volumn 4, Issue 5, 2002, Pages 228-240

  Bosch, Domingo Navarro ^a   Galván, Juan J Cabrera ^a   Ponce, Nicolás Chesa ^a   Díaz Chico, B Nicolás ^a  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

Author keywords

Androgen receptor; Androgen resistance; Gene polymorphisms; Prostatic cancer

Indexed keywords

EID: 84859028782     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/BF02732507     Document Type: Article

References (95)

1. Taplin ME, Ho SM. The endocrinology of prostate cancer. J Clin Endocrinol Metab 2001; 86: 3467-77.
2. Avila DM, Zoppi S, McPhaul MJ. The androgen receptor (AR) in syndromes of androgen insensitivity and in prostate cancer. J Steroid Biochem Mol Biol 2001; 76: 135-42.
3. Culig Z, Hobisch A, Bartsch G, et al. Androgen receptoran update of mechanisms of action in prostate cancer. Urol Res 2000; 28: 211-9.
4. Cude KJ, Dixon SC, Guo Y, et al. The androgen receptor: genetic considerations in the development and treatment of prostate cancer. J Mol Med 1999; 77: 419-26.
5. Ross RK, Pike MC, Coetzee GA, et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998; 58: 4497-504.
6. López-Otín C, Diamandis E P. Breast and prostate cancer: An analysis of common features. Endocr Rev 1998; 19: 365-96.
7. Fernández L, Chirino R, Boada LD, et al. Stanozolol and Danazol, unlike the natural androgens, interact with the low-affinity glucocorticoid binding sites from male rat liver microsomes. Endocrinology 1994; 134: 1401-8.
8. Boada LD, Fernández L, Luzardo OP, et al. Identification of a specific binding site for the anabolic steroid Stanozolol in male rat liver microsomes. J Pharmacol Exptl Therap 1996; 279: 1123-9.
9. Luzardo OP, Machin RP, Diaz-Chico BN, et al. Photoaffinity labeling identification of a specific binding protein for the anabolic steroids stanozolol and danazol: an oligomeric protein regulated by age, pituitary hormones and ethinyl estradiol. Endocrinology 2000; 141: 3377-87.
10. Kumar VL, Majumder PK, Kumar V. Observations on EGFR gene amplification and polymorphism in prostatic diseases. Int Urol Nephrol 2000; 32 (1): 73-5.
11. Chesire DR, Ewing CM, Sauvageot J, et al. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 2000; 45 (4): 323-34.
12. Carruba G, Pfeffer U, Fecarotta E, et al. Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells. Cancer Res 1994; 54: 1190-3.
13. Lau KM, LaSpina M, Long J, et al. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 2000; 60: 3175-82.
14. DiPaola RS, Zang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination in CaP. N Engl J Med 1998; 339: 785-91.
15. Bosland MC. The role of steroid hormones in prostate carcinogenesis, J Natl Cancer Inst (Monogr) 2000; 27: 39-66.
16. Logothetis CJ. A therapeutically relevant framework for the classification of human CaP. Seminars Oncol 1999; 26: 369-74.
17. Yong EL, Lim J, Qi W, et al. Molecular basis of androgen receptor diseases. Ann Med 2000; 32: 15-22.
18. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000; 21: 427-33.
19. Súchil Bernal L. Epidemiología del cáncer de próstata. Rev Oncología 2001; 3: 11-21.
20. Craft N, Shostak, Y, Carey M, et al. A mechanism for hormone-independent prostate cancer modulation of androgen receptor signaling by the HER-2/neu thyrosine kinase. Nature Med 1999; 5: 280-5.
21. Trapman J, Koivisto PA. Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene. Cancer Res 2000; 60 (22): 6479-81.
22. Mononen N, Syrjakoski K, Matikainen M, et al. Genetic linkage analysis of prostate cancer families to Xq27-28. Hum Hered 2001; 51: 107-13.
23. Ewing CM, Bujnovszky P, Carpten JD, et al. Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8 p22-23. Am J Hum Genet 2001; 69: 341-50.
24. Habuchi T, Liqing Z, Suzuki T, et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000; 60: 5710-3.
25. Yamada Y, Watanabe M, Murata M, et al. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5 alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 2001; 92: 683-4.
26. Marcelli M, Ittmann M, Mariani S, Sutherland R. Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60: 944-9.
27. McPhaul MJ. Molecular defects of the androgen receptor. J Steroid Biochem Mol Biol 1999; 69: 315-22.
28. Bousema JT, Bussemakers MJ, van Houwelingen KP, et al. Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia. Eur Urol 2000; 37: 234-8.
29. Ingles SA, Ross RK, Yu MC, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997; 89: 166-70
30. Loy CJ, Yong EL. Sex, infertility and the molecular biology of the androgen receptor. Curr Opin Obstet Gynecol 2001; 13: 315-21.
31. Westberg L, Baghaei F, Rosmond R, et al. Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J Clin Endocrinol Metab 2001; 86: 2562-8.
32. Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol 2001; 116: 452-5.
33. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994; 22: 3181-6.
34. Von Eckardstein S, Syska A, Gromoll J, et al. Inverse correlation between sperm concentration and number of androgen receptor CAG repeats in normal men. J Clin Endocrinol Metab 2001; 86: 2585-90.
35. Wallerand H, Remy-Martin A, Chabannes E, et al. Relationship between expansion of the CAG repeat in exon 1 of the androgen receptor gene and idiopathic male infertility. Fertil Steril 2001; 76: 769-74
36. Krithivas K, Yurgalevitch SM, Mohr BA, et al. Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J Endocrinol 1999; 162: 137-42.
37. Lieberman AP, Fischbeck KH. Triplet repeat expansion in neuromuscular disease. Muscle Nerve 2000; 23: 843-50.
38. Knoke I, Allera A, Wieacker P. Significance of the CAG repeat length in the androgen receptor gene (AR) for the transactivation function of an M780I mutant AR. Hum Genet 1999; 104: 257-61.
39. La Spada AR, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352: 77-9.
40. Djian P, Hancock JM, Chana HS. Codon repeats in genes associated with human diseases: fewer repeats in the genes of nonhuman primates and nucleotide substitutions concentrated at the sites of reiteration. Proc Natl Acad Sci U S A 1996; 93: 417-21.
41. Wellington CL, Ellerby LM, Hackam AS, et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 1998; 273: 9158-67.
42. Abdullah A, Trifiro MA, Panet-Raymond V, et al. Spinobulbar muscular atrophy: polyglutamine-expanded androgen receptor is proteolytically resistant in vitro and processed abnormally in transfected cells. Hum Mol Genet 1998; 7: 379-84.
43. Mifsud A, Choon AT, Fang D, Yong EL. Prostate-specific antigen, testosterone, sex-hormone binding globulin and androgen receptor CAG repeat polymorphisms in subfertile and normal men. Mol Hum Reprod 2001; 7: 1007-13.
44. Giovannucci E, Platz EA, Stampfer MJ, et al. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology 1999; 53: 121-5.
45. Mitsumori K, Terai A, Oka H, et al. Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): correlation with adenoma growth. Prostate 1999; 41: 253-7.
46. Shibata A, Stamey TA, McNeal JE, et al. Genetic polymorphisms in the androgen receptor and type ii 5alphareductase genes in prostate enlargement. J Urol 2001; 166: 1560-4.
47. Platz EA, Rimm EB, Willett WC, et al. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000; 92: 2009-17.
48. Jin B, Beilin J, Zajac J, et al. Androgen receptor gene polymorphism and prostate zonal volumes in Australian and Chinese men. J Androl 2000; 21: 91-8.
49. Irvine RA, Yu MC, Ross RK, et al. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995; 55: 1937-40.
50. Sartor O, Zheng Q, Eastham JA. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology 1999; 53: 378-80.
51. Ekman P, Gronberg H, Matsuyama H, et al. Links between genetic and environmental factors and prostate cancer risk. Prostate 1999; 39: 262-8.
52. Hsing AW, Gao YT, Wu G, et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 2000; 60: 5111-6.
53. Hakimi JM, Schoenberg MP, Rondinelli RH, et al. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Caner Res 1997; 3: 1599-608.
54. Stanford JL, Just JJ, Gibbs M, et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997; 57: 1194-8.
55. Modugno F, Weissfeld JL, Trump DL, et al. Variants of Aromatase and the Androgen and Estrogen Receptors: Toward a Multigenic Model of Prostate Cancer Risk. Clin Cancer Res 2001; 7: 3092-6.
56. Correa-Cerro L, Wohr G, Haussler J, et al. (CAG) nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur J Hum Genet 1999; 7: 357-62.
57. Bratt O, Borg A, Kristoffersson U, et al. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 1999; 81: 672-6.
58. Latil AG, Azzouzi R, Cancel GS, et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001; 92: 1130-7.
59. Beilin J, Harewood L, Frydenberg M, et al. A case-control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects. Cancer 2001; 92: 941-9.
60. Wille AH, Terrell RB, Cheville JC, et al. Focal microsatellite mutations in relatives with prostatic adenocarcinoma. Anticancer Res 1996; 16(6B): 3883-6.
61. Lange EM, Chen H, Brierley K, et al. The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 439-42.
62. Miller EA, Stanford JL, Hsu L, et al. Polymorphic repeats in the androgen receptor gene in high-risk sibships. Prostate 2001; 48: 200-5.
63. Hardy DO, Scher HI, Bogenreider T, et al. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab 1996; 81: 4400-5.
64. Nam RK, Elhaji Y, Krahn MD, et al. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol 2000; 164: 567-2.
65. Schoenberg MP, Hakimi JM, Wang S, et al. Microsatellite mutation (CAG24 - >18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 1994; 198: 74-80.
66. Lumbroso R, Beitel LK, Vasiliou DM, et al. Codon-usage variants in the polymorphic (GGN) n trinucleotide repeat of the human androgen receptor gene. Hum Genet 1997; 101: 43-6.
67. Platz EA, Giovannucci E, Dahl DM, et al. The androgen receptor gene GGN microsatellite and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 1998; 7: 379-84.
68. Linja MJ, Savinainen KJ, Saramaki OR, et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001; 61: 3550-5.
69. Ruizeveld de Winter JA, Janssen PJ, et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994: 144: 735-46.
70. de Vere White R, Meyers F, Chi SG, et al. Human androgen receptor expression in prostate cancer following androgen ablation. Eur Urol 1997; 31: 1-5.
71. Majumder PK, Wadhwa SN, Kumar VL. Androgen receptor transcript level in benign hypertrophy and carcinoma of the human prostate. Urol Int 1997; 59: 2315-20.
72. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314-9.
73. Koivisto PA, Helin HJ. Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma. J Pathol 1999; 189: 219-23.
74. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-6.
75. Koivisto P, Kolmer M, Visakorpi T, et al. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998; 152 (1): 1-9.
76. Gregory CW, Hamil KG, Kim D, et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 1998; 58: 5718-24.
77. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994; 144: 735-46.
78. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61: 4315-9.
79. Henshall SM, Quinn DI, Lee CS, et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 2001; 61: 423-7.
80. Sadar MD, Hussain M, Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer 1999; 6: 487-502.
81. Palmberg C, Koivisto P, Kakkola L, et al. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000; 164: 1992-5.
82. Palmberg C, Koivisto P, Hyytinen E, et al. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol 1997; 31: 216-9.
83. Hakimi JM, Rondinelli RH, Schoenberg MP, et al. Androgen-receptor gene structure and function in prostate cancer. World J Urol 1996; 14: 329-37.
84. Kelly HL, Scher HL. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149: 607-9.
85. Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59: 2511-5.
86. Suzuki H, Akakura K, Komiya A, et al. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996; 29: 153-8.
87. Taylor JA, Hirvonen A, Watson M, et al. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996; 56: 4108-10.
88. Ingles SA, Coetzee GA, Ross RK, et al. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 1998; 58: 1620-3.
89. Allen N, Forrest MS, Key TJ. The association between polymorphisms in the CYP17 and alpha-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev 2001; 10: 185-9.
90. Haiman CA, Stampfer MJ, Giovannucci E, et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 743-8.
91. Yamada Y, Watanabe M, Murata M, et al. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 2001; 92: 683-6.
92. Nam RK, Toi A, Vesprini D, et al. V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 2001; 57 (1): 199-204.
93. Gsur A, Haidinger G, Hinteregger S, et al. Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. Int J Cancer 2001; 95: 152-5.
94. Yang Q, Shan L, Segawa N, et al. Novel polymorphisms in prostate specific antigen gene and its association with prostate cancer. Anticancer Res 2001; 21(1A): 197-200.
95. Tang YM, Green BL, Chen GF, et al. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity and distribution in prostate cancer cases and controls. Pharmacogenetics 2000; 10: 761-6.